ERBB2 and breast carcinoma: We had previously shown that G28UCM improved EGCG effects, alone and in several combinatorial regiments with anti-HER2 drugs and chemotherapy, in parental and trastuzumab- or lapatinib-resistant AU565 HER2 breast cancer cells [29].